Search results for: 'battle of the tech gene'

19 Jan 2023  |  Global  |  Technology Research

Advances in Gene Editing Technologies in Healthcare

Next-generation genome editing tools and improved delivery are bolstering gene editing therapeutics and diagnostics.

Infographics

×

Advancements in gene editing technology are boosting its adoption in various fields, including healthcare, diagnostics, agriculture, and industrial biotechnology. CRISPR, ZFNs, and TALENs are examples of technologies that have revolutionized the gene editing field. Moreover, with constant research efforts, new technologies such as base editing, pri...

The global main battle tank (MBT) market is entering a new phase of modernization and strategic realignment. Rising geopolitical instability, high-intensity conflict scenarios, and growing demand for land-based deterrence capabilities are driving renewed investment cycles across NATO, APAC, and MENA. According to Frost & Sullivan’s Aerospace & Defe...

The acute impact of climate change due to growing GHG emissions highlights the need for the technologies that can reduce said emissions while preparing the world s population for a scenario in which international targets are not achieved. While mitigation technologies seek to reduce or offset GHG emissions, adaptation technologies prepare communiti...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

The Frost & Sullivan research service discusses the cell and gene therapy (CGT) market and highlights some key roadblocks in viral vector manufacturing. While many CGT candidates exist in the pipeline, there is a huge capacity deficit that the industry is collaboratively trying to address. Scalability, costs, reproducibility, and overall process ef...

The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme repl...

16 Aug 2022  |  North America  |  Market Research

Global Cell and Gene Therapy (CGT) Growth Opportunities

The Shift to Prevalent Diseases and Allogeneic Cell Therapies Creates New Growth Opportunities in the CGT Value Chain

Infographics

×

This Frost & Sullivan study examines the global cell and gene therapy (CGT) market. It highlights revenue forecasts and key growth opportunities for CGT market participants based on the evolution of their business models and strategic approaches as well as investments and regulations. The study segments the market by product (cell therapy, gene-mod...

Militaries increasingly operate on congested battlefields that are expanding geographically and across domains while under persistent surveillance that requires fast-paced decision-making through effective situational awareness, intelligence gathering, and action targeting. The battlefield congestion has resulted in slower decision cycles and react...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides a comprehensive overview of breakthrough innovations reshaping biomanufacturing, cell and gene therapy, precision immunotherapy, anti-infectives, and neurotherapeutics across oncology, infectious disease, nephrology, and neurodegenerative disease. It hi...